Sold as Serentil. Every FDA application for this active ingredient. Boxed warning
As of Nov 22, 2026, FDA lists 3 applications for Mesoridazine besylate (sold as Serentil), first approved Feb 27, 1970, with 0 new uses approved and 0 published complete response letters.
| Feb 27, 1970 | SerentilNDA 16774 ยท New molecular entity | Novartis Pharmaceuticals | 46 | Discontinued |
| Feb 27, 1970 | SerentilNDA 16775 ยท New dosage form | Novartis Pharmaceuticals | 26 | Discontinued |
| Jan 31, 1972 | SerentilNDA 16997 ยท New dosage form | Novartis Pharmaceuticals | 28 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA